Navigation Links
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements
Date:7/21/2014

LAVAL, Quebec, July 21, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has contacted both the Autorite des marches financiers ("AMF") in Quebec and the U.S. Securities and Exchange Commission  ("SEC") regarding Allergan Inc.'s (NYSE: AGN) apparent attempt to mislead investors and manipulate the market for Valeant common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information.  The latest misleading statements were made last Friday when Allergan falsely asserted in an SEC filing that Bausch + Lomb's pharmaceutical sales were stagnant or declining. Contrary to Allergan's statements this past Friday, Bausch + Lomb's global prescription pharmaceutical business, which represents less than 20% of Bausch + Lomb total sales, grew approximately 6% in the second quarter of 2014, while the U.S. prescription pharmaceutical business grew 17%, as compared to the prior year, with well over 70% of that growth attributable to volume increases.  Valeant's decision to contact the authorities also reflects concerns raised by several Canadian Valeant shareholders about comments made about Valeant by Allergan's management during recent meetings with these investors in Canada.

"We can no longer tolerate unjustified attacks on Valeant's business and strongly believe we are obligated to take action to protect Valeant shareholders from Allergan's apparent attempts to mislead investors and manipulate the market for Valeant stock," said J. Michael Pearson, chairman and chief executive officer. "Allergan's continued disparagement of Valeant and repeated
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... AUSTIN, Texas, June 29, 2011 Ascension Orthopedics, Inc., the ... the PyroTITAN™ Humeral Resurfacing Implant in Geelong, Australia by Richard ... "The patient was a 57-year-old, active male with ... by a fall from a mountain bike and not improved ...
... 2011 Medicines can cure disease, relieve symptoms, and ... a lot of damage if taken incorrectly, when not ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Studies estimate that up ... be prevented. Learn how FDA—through its Safe ...
Cached Medicine Technology:Ascension Orthopedics Implants PyroTITAN™ in Geelong, Australia 2
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... Ga., USA (PRWEB) January 22, 2015 ... a statewide data management system with support from GEOSYSTEMS, ... , The new solution will leverage Hexagon Geospatial’s ... and vector data as well as point clouds and ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... , , SAN ... Cetyl Max/Flexadren mischaracterized certain facts associated with the ... Board: IAGX). Both companies extend their apologies to ... affected by the mischaracterization. , , ...
... , , MINNEAPOLIS, Aug. 13 ... will be the new Director of Research for the organization. Dr. ... of Oregon and the University of Minnesota. , , ... Minnesota and our research department," said David Willoughby, Chief Executive Officer ...
... activity reduces depression and fatigue , THURSDAY, Aug. 13 ... and depression experienced by leukemia patients who are undergoing ... people who did individualized exercise sessions while in the ... induction phase of leukemia treatment. The sessions included aerobic ...
... so high , , THURSDAY, Aug. 13 (HealthDay News) -- ... and policymakers would like, two U.S. health agencies have decided ... Centers for Disease Control and Prevention and the Office of ... and Human Services, are spending much of Thursday at CDC ...
... , SAN JOSE, Calif., Aug. 13 Human Pheromone Sciences, ... for the three and six months ended June 30, 2009. For the ... a 5% decrease from the revenues of $236,000 in the prior year ... as compared with a net loss of $88,000 ($0.02 per share) for ...
... ... health care plan currently under consideration in Congress. After pouring through the entire document, he ... is no coverage for illegal aliens, and the parental education is largely voluntary, and driven ... financial side. , ...
Cached Medicine News:Health News:Exercise May Help in Leukemia Recovery 2Health News:It's Time for More Moms to Breast-Feed, U.S. Officials Say 2Health News:It's Time for More Moms to Breast-Feed, U.S. Officials Say 3Health News:Human Pheromone Sciences Announces Second Quarter Results 2Health News:Human Pheromone Sciences Announces Second Quarter Results 3Health News:Human Pheromone Sciences Announces Second Quarter Results 4Health News:Analysis of the Proposed Health Care Legislation Finds Financial Aspects May be Difficult to Forecast 2
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
... mobile flow cytometer for any kind ... counting. The CyFlow SL analyzes forward ... with up to 3 fluorescence channels. ... is performed with a PC or ...
The Elecsys 2010 Rack System streamlines processes and allows for smooth implementation of laboratory automation....
... an automated, multiparametric immunoassay system. ... stores the calibration in the ... cost-per-patient result. Plus, with its ... of use and uni/bi-directional interface, ...
Medicine Products: